Файловый архив студентов. Файловый архив студентов.
1330 вузов, 5508 предметов.
/ Регистрация
FAQ Обратная связь Вопросы и предложения
Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Ростовский Государственный Медицинский Университет
Предмет:
Медицина общая
Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_4624_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
13 Мб
Скачать
☆
5 A Proposal foraConsistent Classication ofNasal Vestibule Carcinomas
https://t.me/medicina_free
Fig. 5.4 Nose vestibule SCC extends to the skin passing between the alar and lateral cartilage. According to the current proposal, this would be classied as a cT2a; in Wang’s classication, it is a T2; in AJCC classication, it is a cT4a
53
54
https://t.me/medicina_free
Fig. 5.5 Tumor growth determines a destruction of nose tip cartilages, with skin invasion, without bony invasion. According to the current proposal, this would be classied as a cT2b; in Wang’s classication it is a T2; in AJCC classication, it is a cT4a
F. Bussu et al.
Fig. 5.6 The lesion extends beyond the pyriform aperture along the nasal septum. According to the current proposal, this would be classied as a cT3, in Wang and AJCC classication, it is a T1
ab
5 A Proposal foraConsistent Classication ofNasal Vestibule Carcinomas
https://t.me/medicina_free
Fig. 5.7 The lesion invades bony structures as nasal bones (a) or hard palate (b). According to the current proposal, these would be classied as a cT4a, in Wang classication as T3, in AJCC as cT1 (a) or cT3 (b)
Fig. 5.8 The lesion sliding along the deep surface of nasal bones invades the intracranial space. In this case, the lesion is a cT4b according to both the current proposal and AJCC classication and T3 according to Wang classication
55
References
1. Gray H.Anatomy of the human body. Philadelphia: Lea & Febiger.
2. Jeannon JP, Riddle PJ, Irish J, O'Sullivan B, Brown DH, Gullane P.Prognostic indicators in carcinoma of the nasal vestibule. Clin Otolaryngol. 2007;32(1):19–23.
3. Bussu et al. New standards for the management of nose vestibule malignancies Acta Oto­Laryngologica. 2023;143(3):215–22. https://doi.org/10.1080/00016489.2023.2179662.
4. Horsmans JD, Godballe C, Jorgensen KE, Bastholt L, Lontoft E.Squamous cell carcinoma of the nasal vestibule. Rhinology. 1999;37(3):117–21.
5. Amin MB.AJCC cancer staging manual, vol. 17. 8th ed. Berlin: Springer International; 2017. p.1032.
6. Bussu F, Tagliaferri L, Piras A, Rizzo D, Tsatsaris N, De Corso E et al. Multidisciplinary approach to nose vestibule malignancies: setting new standards Approccio mul­tidisciplinare ai tumori maligni del vestibolo del naso: verso la denizione di nuovi standard Acta Otorhinolaryngologica Italica. 2021;41(Suppl. 1):S158–S165
https://doi.org/10.14639/0392-100X-suppl.1-41-2021-16.
56
https://t.me/medicina_free
7. Vital D, Morand G, Huber GF, Studer G, Holzmann D.Outcome in squamous cell carcinoma of the nasal vestibule: a single center experience. Head Neck. 2015;37(1):46–51.
8. Poulsen M, Turner S.Radiation therapy for squamous cell carcinoma of the nasal vestibule. Int J Radiat Oncol Biol Phys. 1993;27(2):267–72.
9. Mendenhall WM, Stringer SP, Cassisi NJ, Mendenhall NP.Squamous cell carcinoma of the nasal vestibule. Head Neck. 1999;21(5):385–93.
10. Kummer E, Rasch CR, Keus RB, Tan IB, Balm AJ.T stage as prognostic factor in irradiated localized squamous cell carcinoma of the nasal vestibule. Head Neck. 2002;24(3):268–73.
11. Wang CC. Treatment of carcinoma of the nasal vestibule by irradiation. Cancer. 1976;38(1):100–6.
12. Agger A, von Buchwald C, Madsen AR, Yde J, Lesnikova I, Christensen CB, etal. Squamous cell carcinoma of the nasal vestibule 1993-2002: a nationwide retrospective study from DAHANCA.Head Neck. 2009;31(12):1593–9.
13. Bussu F, Tagliaferri L, De Corso E, Passali GC, Lancellotta V, Mattiucci GC, etal. Functional results of exclusive interventional radiotherapy (brachytherapy) in the treatment of nasal ves­tibule carcinomas. Brachytherapy. 2020;20:178.
14. Bussu F, Tagliaferri L, Mattiucci G, Parrilla C, Dinapoli N, Micciche F, etal. Comparison of interstitial brachytherapy and surgery as primary treatments for nasal vestibule carcinomas. Laryngoscope. 2016;126(2):367–71.
15. Bussu F, Tagliaferri L, Mattiucci G, Parrilla C, Rizzo D, Gambacorta MA, etal. HDR interven­tional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies. Head Neck. 2019;41(6):1667–75.
16. Tagliaferri L, Fionda B, Bussu F, Parrilla C, Lancellotta V, Deodato F, et al. Interventional radiotherapy (brachytherapy) for squamous cell carcinoma of the nasal vestibule: a multidisci­plinary systematic review. Eur J Dermatol. 2019;29(4):417–21.
17. Dowley A, Hoskison E, Allibone R, Jones NS.Squamous cell carcinoma of the nasal vestibule: a 20-year case series and literature review. J Laryngol Otol. 2008;122(10):1019–23.
18. Chabrillac E, Talawdekar A, Garikipati S, Varley I, Sionis S, Beasley N, etal. A single cen­tre’s experience of 23 cases of total rhinectomy for the treatment of squamous cell carcinoma involving the nasal vestibule. Eur Arch Otorhinolaryngol. 2022;279:2069.
19. Scheurleer WFJ, Tagliaferri L, Rijken JA, Crescio C, Rizzo D, Mattiucci GC, Pameijer FA, de Bree R, Fionda B, de Ridder M, Bussu F. Evaluation of Staging Systems for Cancer of the Nasal Vestibule Cancers. 2023;15(11):3028. https://doi.org/10.3390/cancers15113028.
F. Bussu et al.
Acknowledged Therapeutic Options
https://t.me/medicina_free
inNose Vestibule Malignancies
TropianoPaolo, FoisPaolo, MelisAndrea, LauraMariaDe Luca, FrancescoMiccichè, DiMarioDalila, AndreaD’Aviero, GiovanniMariaFadda, LucaTagliaferri, andDavideRizzo
6.1 Introduction
SCC is the most frequent malignancy of the nose vestibule, it is considered to account for <1% of head and neck malignant lesions [1], but its prevalence is prob­ably underestimated (see Chaps. 3 and 16) [2, 3]. As early symptoms are lacking and mostly analog to infectious/inammatory processes (vestibulitis) or traumatic lesions, diagnosis is often delayed. This leads to a sure, even if difcult to quantify,
6
T. Paolo · F. Paolo · M. Andrea · L. M. De Luca (*) Otolaryngology Division, Azienda Ospedaliero Universitaria Sassari, Sassari, Italy e-mail: andrea.melis@aouss.it
F. Miccichè · A. D’Aviero · L. Tagliaferri Radiotherapy Division, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy e-mail: luca.tagliaferri@policlinicogemelli.it
D. M. Dalila Radiation Oncology Division, Sassari University Hospital, Sassari, Italy
G. M. Fadda Medical Oncology Division, Sassari University Hospital, Sassari, Italy e-mail: giovanni.fadda@aouss.it
D. Rizzo Otolaryngology Division, Azienda Ospedaliero Universitaria Sassari, Sassari, Italy
Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy e-mail: drizzo@uniss.it
© Springer Nature Switzerland AG 2023 F. Bussu (ed.), Malignancies of the Nasal Vestibule,
https://doi.org/10.1007/978-3-031-32850-3_6
57
58
https://t.me/medicina_free
T. Paolo et al.
impact on survival [4] and viable therapeutic options because of almost constant tumoral extension to adjacent structures (e.g., skin, nasal cavities and paranasal sinuses, superior lip, nasal septum or bones) at diagnosis [5].
Due to the relative rarity of this malignancy and to the frequent misdiagnosis (see Chaps. 3, 5, and 16), there are no univocal recommendations for treatment choice. Both surgery and radiotherapy (RT) are generally accepted modalities for rst-line treatment of primary tumor (T) and regional metastasis (N). However, in the litera­ture most of the described series are small and involve patients primarily treated with only one modality with just few works describing larger series and/or compar­ing different treatment modalities (e.g., surgical versus non-surgical).
Comparison of different studies is further complicated by the absence of consen­sus concerning the staging system, and also among the works cited in the following paragraphs, T classication has been non-consistently alternatively dened using AJCC or Wang classication (and in some cases, even NMSC AJCC classica­tion) [6].
In Table6.1, a summary of the literature evidence concerning the different treat­ment modalities for primary NVSCC is reported.
6 Acknowledged Therapeutic Options inNose Vestibule Malignancies
https://t.me/medicina_free
Adjuvant/complementary
EBRT
No curative treatment/
BSC/lost
Primary
IRT
59
(continued)
Primary EB
Primary
No of
Table 6.1 Main literature series of nasal vestibule, with a summary of populations described and treatment strategies
RT
surgery
patients
6 6 (100%) 0 0 0 0
histologies
Year Histology
Author
DesPrez [42] 1967 Mixed
56 (100%) 0 0 0
0 914 (55%) 762 (45%) 0 0
a
Baris [23] 1985 SCC 22 0 0 22 (100%) 0 3 (14%)
Wong [24] 1986 SCC 56 0
1987 SCC 27 0 8 14 5 8
Mendenhall
[44]
Chobe [27] 1988 SCC 32 0 21(66%) 11 (34%) 0 0
Mazeron [45] 1989 BCC and SCC 1668
Levendag [28] 1990 SCC 63 0 18 (29%) 45 (71%) 0 8 (13%)
1984 SCC 13 0 6 (46%) 7 (54%) 0 3 (23%)
Haynes [26] 1974 SCC 22 0(0%) 9 (40%) 13 (60%) 0 0
Goepfert [7] 1974 SCC 26 10 (38%) 16 (62%) 0 0 0
Wang [18] 1976 SCC 36 0 NP NP 5 NP
Mak [19] 1980 BCC and SCC 47 3 (6%) 41 (88%) 2 (4%) 1 2 (4%)
Kagan [8] 1981 SCC 42 28 (67%) 14 (33%) 0 0 13 (31%)
De Jong [20] 1981 SCC 22 9 (40%) 13 (60%) 0 0 0
Johansen [22] 1984 SCC 66 7 (11%) 56 (85%) 0 3 NP
Mendenhall
[43]
1993 SCC 39 0 12 (31%) 27 (69%) 0 18 (46%)
Patel [10] 1992 SCC 30 10 (33%) 0 20 (67%) 0 23 (77%)
Poulsen [30] 1993 SCC 29 7 (24%) 22 (76%) 0 0 7 (24%)
McCollough
[46]
60
https://t.me/medicina_free
Adjuvant/complementary
EBRT
No curative treatment/
BSC/lost
Primary
IRT
T. Paolo et al.
Primary EB
RT
Primary
surgery
No of
patients
Year Histology
Author
Table 6.1 (continued)
1994 SCC 25 21 (84%) 4 (16%) 0 0 11 (44%)
Pantelakos
[11]
Turner [31] 1995 SCC 21 0 21 (100%) 0 0 0
1999 SCC 60 0 16 (27%) 44 (73%) 0 31 (52%)
Evensen [32] 1996 SCC 23 4 (17%) 0 19 (83%) 0 7 (30%)
Mendenhall
[33]
0 56 (100%) 0 0 47 (84%)
h
2004 SCC 56
Fornelli [12] 2000 SCC 32 23 (72%) 9 (28%) 0 0 8 (25%)
Langendijk
[35]
14 (22%) 0 50 (78%) 0 14 (22%)
i
Levendag [29] 2006 BCC and SCC 64
Jeannon [25] 2007 SCC 84 17 (20%) 65 (77%) 0 2 (3%) 10 (12%
SCC 174 50 (29%) 120 (69%) 0 4 (2%) 28 (16%)
Wallace [47] 2007 SCC 79 0 24 (30%) 55 (70%) 0 42 (53%)
Dowley [4] 2008 SCC 26 12 (46%) 14 (54%) 0 0 2 (8%)
Agger [13] 2009
2013 SCC 10 10 (100%) 0 0 0 2 (20%)
2014 SCC 30 30 (100%) 0 0 2 (7%) 7 (23.3%)
Ladderose
[14]
Koopmann
[48]
Lipman [36] 2014 SCC 83 11 (13%) 9 (11%) 60 (72%) 1 (1.2%) 14 (17%)
Vital [1] 2014 SCC 30 21 (70%) 9 (30%) 0 2 (7%) 6 (20%)
Wray [34] 2015 SCC 99 13 (13%) 39 (39%) 15 (15%) 1 (1%) 52 (52%)
Bussu [39] 2016 SCC 12 6 (50%) 0 6 (50%) 0 0
Taxy 2016 SCC 5 5 (100%) 0 0 0 3 (60%)
Vanneste [38] 2016 SCC 81 0 38 (47%) 41 (51%) 0 2 (2%)
6 Acknowledged Therapeutic Options inNose Vestibule Malignancies
https://t.me/medicina_free
61
Adjuvant/complementary
EBRT
No curative treatment/
BSC/lost
Primary
IRT
Primary EB
RT
RFS
100%
100%
Primary
management of
N0 OS DSS
(2yrs)
73%
(2yrs)
(2yrs)
(2yrs)
(2yrs)
NP 77%
(2yrs)
(5yrs)
(continued)
Primary
surgery
No of
patients
Year Histology
2018 SCC 141 0 0 102 (72%) 0 0
Author
Czerwinski
[37]
2020 SCC 16 16 (100%) 0 3 (19%) 0 0
Zaoui [5] 2018 SCC 26 26 (100%) 0 0 0 2 (8%)
Federspril
2020 SCC 14 0 0 14 (100%) 0 0
[15]
Tagliaferri
2021 SCC 45 45 (100%) 0 0 0 0
[40]
Lambertoni
2021 SCC 23 23 (100%) 0 0 0 17 (73.9%)
[16]
Chabrillac
2022 SCC 225 0 65 (29%) 153 (68%) 0 7 (3%)
[17]
Czerwinski
[41]
AJCC T
classication N classication
Wang T
classication
Recurrences
Primary
6 (100%) 0 NP NP NP Observation 83%
22 (100%) 0 NP NP NP Observation NP 86%
20 (77%) 6 (23%) NP NP AJCC Observation 78%
36 (100%) 0 Ye s NP AJCC Observation NP NP 74%
45 (96%) 2 (4%) NP NP NP Observation NP NP 67%
42 (100%) 0 NP NP NP NP 64% 74% 64%
62
https://t.me/medicina_free
T. Paolo et al.
RFS
Primary
management of
N0 OS DSS
77%
(3yrs)
100%
(5yrs)
(5yrs)
80%
87%
(5yrs)
NP
(5yrs)
91%
(5yrs)
(2yrs)
(2yrs)
b
(5yrs)
NP
c
90% 80%
(5yrs)
(5yrs)
NP 61%
e
54%
d
(5yrs)
81%
86%
(3yrs)
(3yrs)
(3yrs)
AJCC T
classication N classication
Wang T
classication
Recurrences
Primary
22 (100%) 0 Ye s NP NP Observation NP NP 50%
NP NP Ye s NP AJCC Observation 61.4% 79% 59%
Table 6.1 (continued)
8 (62%) 5 (38%) NP AJCC skin AJCC ENI 71%
19 (84%) 3 (14%) NP NP NP ENI 92% 95% 95%
56 (100%) 0 NP NP NP Observation 64%
15 (68%) 7 (32%) NP AJCC skin AJCC ENI 77%
32(100%) 0 NP NP NP ENI NP NP 87.5%
1356 (81%) 312 (19%) NP NP NP NP NP NP 93%
63 (100%) 0 Ye s NP AJCC NP 65%
30 (100%) 0 Ye s NP AJCC NP NP ~80%
29 (100%) 0 NP AJCC skin AJCC Observation 64%
25 (100%) 0 NP NP NP Observation NP 8 52%
29 (74%) 10 (26%) NP AJCC skin AJCC Mixed 75% ~90%
21 (100%) 0 NP NP NP Observation 57%
23 (100%) 0 NP AJCC skin AJCC Observation 78% 96% 87%
Соседние файлы в папке Библиотека им академика М.И. Перельмана
Помощь Обратная связь Вопросы и предложения Пользовательское соглашение Политика конфиденциальности